| http://purl.uniprot.org/citations/16257849 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/16257849 | http://www.w3.org/2000/01/rdf-schema#comment | "This study was conducted as part of International Life Sciences Institute (ILSI) program to evaluate the carcinogenic potential of clofibrate, a nongenotoxic, peroxisome proliferator-activated receptor (PPAR) alpha agonist, following oral administration to p53+/-heterozygous mice for a minimum of 26 weeks. p-Cresidine, a urinary bladder carcinogen, was given orally at 400 mg/kg/day as a positive control. Initial clofibrate doses were 50, 250, and 400 mg/kg/day for males and 50, 200, and 500 mg/kg/day for females. Due to unexpected mortality during the first week of dosing, clofibrate doses were lowered to 25, 75, and 100 mg/kg/day for males and 25, 75, and 125 mg/kg/day for females. Clinical signs and mortality were greater in p53+/-than wild-type (WT) mice. With the exception of liver weights, no marked differences in any other parameters either between the sexes or between WT and p53+/-mice were noted. Moderate increases in liver weights noted in WT males given 100 mg/kg/day clofibrate were not associated with any microscopic changes. No neoplastic response was observed in p53+/-mice after 6 months of exposure to clofibrate at doses up to 100 mg/kg/day for males and 125 mg/kg/day for females. Transitional-cell hyperplasia and carcinoma of the urinary bladder were noted in both sexes given p-cresidine, demonstrating that the p53+/-mouse responded to a known mouse carcinogen as expected. Clofibrate produced non-neoplastic findings in the adrenals, pancreas, and prostate, whereas p-cresidine affected the kidney, liver, pancreas, and spleen."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.org/dc/terms/identifier | "doi:10.1080/10915810500210237"xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/author | "Mann P.C."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/author | "Allen J.S."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/author | "Campbell J.A."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/author | "Miller R.T."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/author | "Hoivik D.J."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/author | "Rickert D."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/author | "Santostefano M.J."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/author | "Savina P.M."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/author | "Selinger K."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/author | "Torrey C.E."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/date | "2005"xsd:gYear |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/name | "Int J Toxicol"xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/pages | "289-299"xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/title | "Evaluation of the carcinogenic potential of clofibrate in the p53+/- mouse."xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://purl.uniprot.org/core/volume | "24"xsd:string |
| http://purl.uniprot.org/citations/16257849 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/16257849 |
| http://purl.uniprot.org/citations/16257849 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/16257849 |
| http://purl.uniprot.org/uniprot/#_A0A158SIS7-mappedCitation-16257849 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16257849 |
| http://purl.uniprot.org/uniprot/#_A0A5Q0MU23-mappedCitation-16257849 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16257849 |
| http://purl.uniprot.org/uniprot/#_I7HIK9-mappedCitation-16257849 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16257849 |
| http://purl.uniprot.org/uniprot/#_P02340-mappedCitation-16257849 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16257849 |
| http://purl.uniprot.org/uniprot/#_Q3UGQ1-mappedCitation-16257849 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16257849 |